Abstract
Already in the year 1810 (Brande) was magnesium proposed as prophylactic treatment against renal stone disease. It was later shown that magnesium increased the solubility of calcium oxalate in vitro (Hammarsten, 1929). Desmars and Tawashi (1973) demonstrated the greater solubility product for magnesium oxalate than for calcium oxalate and magnesium has also been found to account for 20% of the total inhibitory activity of calcium phosphate precipitation in whole urine (Bisaz et al., 1978).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
de Albuquerque, P. F., Tuma, M.: Investigations on urolithiasis. II: Studies on oxalate. J. Urol. 87: 504 (1962).
Bisaz, S., Felix, R., Neumann, W. F., Fleisch, H.: Quantitative determination of inhibitors of calcium phosphate precipitation in whole urine. Mineral Electrolyte Metab. 1: 74 (1978).
Brande, W. T.; Observations on the effects of magnesia in preventing an increased formation of uric acid; with some remarks on the composition of urine. Med. Phys. J. 24: 203 (1810).
Danielson, B. G., Johansson, G., Ljunghall, S.: Magnesium metabolism in healthy subjects. Scand. J. Urol. Nephrol. 51 (suppl): 49 (1979).
Desmars, J. F., Tawashi, R.: Dissolution and growth of calcium oxalate monohydrate. I. Effect of magnesium and pH. Biochim. Biophys. Acta 313: 256 (1973).
Gershoff, S. N., Prien, E. L.: Effect of daily MgO and vitamin B6 administration to patients with recurring calcium oxalate kidney stones. Am. J. Clin. Nutr. 20: 393 (1967).
Hammarsten, G.: On calcium oxalate and its solubility in the presence of inorganic salts with special reference to the occurrence of oxaluria. C R Lab. Carlsberg 17: 1 (1929).
Johansson, G., Backman, U., Danielson, B. G., Ljunghall, S., Wikström, B.: Magnesium metabolism in renal stone disease. Invest. Urol. 18: 93 (1980a).
Johansson, G., Backmann, U., Danielson, B. G., Fellström, B., Ljunghall, S., Wikström, B.: Biochemical and clinical effects of the prophylactic treatment of renal calcium stones with magnesium hydroxide. J. Urol. 124: 770 (1980b).
Johansson, G., Backman, U., Danielson, B. G., Fellström, B., Ljunghall, S., Wikström, B.: Prophylactic treatment with magnesium hydroxide in renal stone disease. In: Urolithiasis: Clinical and basic research. (Ed. L. H. Smith ), pp 267–274. Plenum Publishing Corporation, 1981.
Wikström, B., Backman, U., Danielson, B. G., Fellström, B., Johansson, G., Ljunghall, S.: Urinary citrate excretion and acidification defects in renal calcium stone formers. In: Urolithiasis: Clinical and basic research. (Ed. L. H. Smith ), pp 757–762. Plenum Publishing Corporation, New York, 1981.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1982 Dr. Dietrich Steinkopff Verlag, GmbH & Co. KG, Darmstadt
About this paper
Cite this paper
Johansson, G., Backman, U., Danielson, B.G., Fellström, B., Ljunghall, S., Wikström, B. (1982). Prophylactic treatment of renal stone disease with magnesium hydroxide during five years. In: Gasser, G., Vahlensieck, W. (eds) Pathogenese und Klinik der Harnsteine IX. Fortschritte der Urologie und Nephrologie, vol 20. Steinkopff. https://doi.org/10.1007/978-3-642-72360-5_59
Download citation
DOI: https://doi.org/10.1007/978-3-642-72360-5_59
Publisher Name: Steinkopff
Print ISBN: 978-3-7985-0608-4
Online ISBN: 978-3-642-72360-5
eBook Packages: Springer Book Archive